If you’re considering or already on testosterone replacement therapy, TRT cardiovascular health is probably the question that keeps you up at night more than any other. Headlines have swung wildly over the past decade — first warning that testosterone raises heart attack risk, then more recent, better-designed trials suggesting the opposite. For first responders and performance-focused men who depend on cardiovascular fitness to do their jobs, getting a straight answer matters. Here’s what the current evidence actually shows, and what monitoring on therapy should look like.
Where the Cardiovascular Concern Came From
Early observational studies in the 2010s, including a widely publicized VA cohort analysis, suggested testosterone therapy might increase rates of heart attack and stroke in older men with existing cardiovascular disease. Those findings triggered an FDA label warning in 2015 and years of clinical caution. But observational data is prone to confounding — men prescribed testosterone in those studies often already had more risk factors than untreated men, which muddies any causal claim.
The picture changed substantially with the TRAVERSE trial, a large randomized, placebo-controlled study published in 2023 specifically designed to answer the cardiovascular safety question. It found no increased risk of major adverse cardiac events — heart attack, stroke, or cardiovascular death — in men with low testosterone and existing cardiovascular risk factors treated with testosterone gel versus placebo. This is currently the strongest evidence available, and it prompted the FDA to remove the boxed warning tied to cardiovascular risk in 2025.
What TRT Does to Blood Pressure
Modest Increases Are Common
Some patients report a small rise in systolic blood pressure after starting testosterone therapy, particularly in the first few months. Clinical studies suggest this effect is generally modest — a few points, not a dramatic spike — but it’s worth tracking, especially if you already run on the higher end of normal. Fluid retention and increased red blood cell mass both may contribute to this shift.
When to Flag It
If home readings consistently run above 140/90 after starting therapy, that’s worth a conversation with your provider about dose adjustment, delivery method, or adding a standard antihypertensive. Blood pressure elevation on TRT is manageable in most cases and rarely a reason to stop treatment outright.
Hematocrit: The Number That Actually Needs Watching
If there’s one cardiovascular-adjacent lab value that deserves real attention on testosterone therapy, it’s hematocrit. Testosterone stimulates red blood cell production, and in some men that pushes hematocrit above the normal range — a condition called secondary erythrocytosis or polycythemia. Elevated hematocrit thickens the blood, which may increase the risk of clotting events, including deep vein thrombosis and, in rare cases, stroke.
Who’s Most at Risk
Men using injectable testosterone cypionate, particularly at higher doses or with peak-trough swings from infrequent dosing, tend to see larger hematocrit increases than those on more stable delivery methods. Smokers, men at higher altitude, and those with underlying sleep apnea are also more prone to elevated hematocrit on therapy.
Standard Monitoring Protocol
Most protocols call for a baseline hematocrit before starting therapy, a recheck around the three-month mark, and then every six to twelve months once stable. If hematocrit climbs above roughly 54%, providers typically pause therapy, lower the dose, switch delivery method, or in some cases recommend therapeutic phlebotomy (blood donation) to bring levels back down.
Lipids and Cardiovascular Risk Markers
Testosterone therapy’s effect on cholesterol is generally modest and mixed in the research. Some studies show small reductions in HDL cholesterol on therapy, while LDL and triglyceride effects vary by individual and baseline metabolic status. For most men, these shifts are minor compared to the metabolic improvements — better insulin sensitivity, reduced visceral fat, improved lean mass — that often accompany correcting a genuine testosterone deficiency. A standard lipid panel alongside routine labs helps track any individual trend.
What Monitoring Should Actually Look Like on Therapy
A reasonable cardiovascular monitoring schedule for men on TRT includes baseline and follow-up hematocrit, periodic blood pressure checks (home monitoring between visits is ideal for shift workers whose schedules make morning clinic visits difficult), a lipid panel at baseline and annually, and an honest conversation about family cardiovascular history before starting. Men with existing heart disease, uncontrolled hypertension, or a history of blood clots should have a more cautious, closely supervised approach.
None of this monitoring is unique to testosterone — it’s the same basic diligence that should accompany any long-term hormone therapy. RespondWell’s testosterone cypionate program includes structured lab follow-up specifically to track hematocrit, lipids, and blood pressure over time, rather than a one-and-done prescription.
FAQ
Does TRT increase heart attack risk?
The best current evidence, including the large randomized TRAVERSE trial, found no increased risk of heart attack, stroke, or cardiovascular death in men treated with testosterone versus placebo. Earlier observational studies suggesting higher risk had significant confounding limitations.
How often should hematocrit be checked on TRT?
Typically at baseline before starting, again around three months in, then every six to twelve months once levels are stable. Men on injectable testosterone or with other risk factors for elevated red blood cell counts may need more frequent checks.
Can I stay on TRT if my blood pressure goes up?
In most cases, yes — modest blood pressure increases on therapy are manageable through dose adjustment, delivery method changes, or standard blood pressure medication, and rarely require stopping TRT altogether. Sustained readings above 140/90 should be discussed with your provider.
Get Monitored the Right Way
TRT cardiovascular health isn’t something to guess about. If you’re considering testosterone therapy or already on it without structured lab follow-up, RespondWell builds cardiovascular monitoring — hematocrit, blood pressure, and lipids — directly into every treatment plan. Start your evaluation with RespondWell and get therapy backed by real follow-up, not a one-time prescription.